MedWatch

Experts: Mandatory release of patents highly unlikely

The political debate revolving around whether forcibly released patents can push vaccine production forward has no basis in reality, according to pharmaceutical industry legal experts.

Photo: CHARLY TRIBALLEAU/AFP / AFP

The European supply of vaccines will not be increased by forcing pharmaceutical companies to release their patents, and even if this had been the case, the current vaccine production has progressed to a point where notions of mandatory patent releases will be quite outdated and irrelevant in a few months.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs